NASDAQ: PPBTPurple Biotech Ltd Stock
$1.62-0.06 (-3.57%)
Updated Jun 8, 2023
PPBT Price
$1.62
Fair Value Price
$2.44
Market Cap
$32.14M
52 Week Low
$1.32
52 Week High
$2.80
P/E
N/A
P/B
0.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$19.25M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$6M
Beta
0.88
Next Earnings
Aug 3, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PPBT Overview
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PPBT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PPBT ($1.62) is undervalued by 33.53% relative to our estimate of its Fair Value price of $2.44 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PPBT ($1.62) is significantly undervalued by 33.53% relative to our estimate of its Fair Value price of $2.44 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PPBT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more PPBT due diligence checks available for Premium users.
Be the first to know about important PPBT news, forecast changes, insider trades & much more!
PPBT News
Valuation
PPBT fair value
Fair Value of PPBT stock based on Discounted Cash Flow (DCF)
Price
$1.62
Fair Value
$2.44
Undervalued by
33.53%
PPBT ($1.62) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PPBT ($1.62) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PPBT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
11.75x
Market
52.58x
PPBT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.69x
Industry
5.24x
PPBT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PPBT's financial health
Profit margin
Revenue
$0.0
Net Income
$4.9M
Profit Margin
0%
PPBT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$53.1M
Liabilities
$6.0M
Debt to equity
0.13
PPBT's short-term assets ($24.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PPBT's short-term assets ($24.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PPBT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
$12.6M
Financing
$264.0k
PPBT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PPBT vs Biotech Stocks
Purple Biotech Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.